In the article by Wilson et al, “Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association,” which published ahead of print on April 15, 2021, and appeared in the May 18, 2021, issue of the journal (Circulation. 2021;143:e963–e978. DOI: 10.1161/CIR.0000000000000969), corrections were needed.

On page e972, left column, last paragraph, the second sentence, new reference 59a replaced reference 39. The sentence now reads, “A recent study in the United Kingdom suggested that a single dose of clindamycin may cause complications, including death, from Clostridioides difficile infection.^59a

On page e973, in Table 5, the following updates to the formatting have been made:

In the second column, “Agent,” second row, “Unable to take oral medication,” the second entry “Cefazolin or ceftriaxone,” has been moved down to align with “1 g IM or IV.”

In the second column, “Agent,” third row, “Allergic to penicillin or ampicillin—oral,” the second entry, “Cefazolin or ceftriaxone,” has been moved down to align with “500 mg.”

In the third column, “Adults,” third row, “Allergic to penicillin or ampicillin—oral,” the third entry, “100 mg,” has been moved down to its own cell to align with “Doxycycline” in the second column, third row.

In the fourth column, “Children,” third row, “Allergic to penicillin or ampicillin—oral,” the second and third entries, “<45 kg, 2.2 mg/kg” and “>45 kg, 100 mg” have been moved down to their own cell to align with “Doxycycline” in the second column, third row.

On page e973, in Table 5, the fourth column, third row, the second entry read, “<45 kg, 4.4 mg/kg.” It has been updated to read, “<45 kg, 2.2 mg/kg.”

On page e978, new reference 59a has been added. It reads,

Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. J Antimicrob Chemother. 2015;70:2382–2388. doi: 10.1093/jac/dkv115

On page e978, reference 68 read,

Jones TD, Baumgartner L, Bellows MT, Breese BB, Kuttner AG, McCarty M, Rammelkamp CH; on behalf of the Committee on Prevention of Rheumatic Fever and Bacterial Endocarditis, American Heart Association. Prevention of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Circulation. 1955;11:317–320.

It has been replaced by,

Khalil D, Hultin M, Rashid MU, Lund B. Oral microflora and selection of resistance after a single dose of amoxicillin. Clin Microbiol Infect. 2016;22:949.e1-949.e4. doi: 10.1016/j.cmi.2016.08.008

On page e978, reference 69 read,

Mortimer EA Jr, Rammelkamp CH Jr. Prophylaxis of rheumatic fever. Circulation. 1956;14:1144–1152. doi: 10.1161/01.cir.14.6.1144

It has been replaced by,

Woodman AJ, Vidic J, Newman HN, Marsh PD. Effect of repeated high dose prophylaxis with amoxicillin on the resident oral flora of adult volunteers. J Med Micrbiol. 1985:19:15-23. doi: 10.1099/00222615-19-1-15

These corrections have been made to the current online version of the article, which is available at https://www.ahajournals.org/doi/10.1161/CIR.0000000000000969

在 Wilson 等人的文章“Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association”中，该文章于 2021 年 4 月 15 日提前出版，并出现在 2021 年 5 月 18 日的期刊（Circulation . 2021;143:e963–e978. DOI: 10.1161/CIR.0000000000000969），需要更正。

在第 e972 页，左栏，最后一段，第二句，新的参考文献 59a 替换了参考文献 39。这句话现在写着，“英国最近的一项研究表明，单剂克林霉素可能会导致来自梭菌的并发症，包括死亡艰难梭菌感染。^59a

在页 e973 的表 5 中，对格式进行了以下更新：

在第二列“代理”中，第二行“无法服用口服药物”，第二个条目“头孢唑啉或头孢曲松”已向下移动以与“1 克 IM 或 IV”对齐。

在第二列，“药剂”，第三行，“对青霉素或氨苄西林过敏——口服”，第二个条目“头孢唑啉或头孢曲松”已下移至“500 毫克”。

在第三列，“成人”，第三行，“对青霉素或氨苄西林过敏——口服”，第三个条目“100 毫克”已移至其自己的单元格中，以与第二列中的“强力霉素”对齐，第三行。

在第四列，“儿童”，第三行，“对青霉素或氨苄西林过敏——口服”，第二和第三个条目“<45 kg, 2.2 mg/kg”和“>45 kg, 100 mg”已移动向下到他们自己的单元格以与第二列第三行中的“强力霉素”对齐。

在第 e973 页的表 5 中，第四列第三行的第二个条目是“<45 kg，4.4 mg/kg”。已更新为“<45 kg，2.2 mg/kg”。

在 e978 页上，添加了新的参考文献 59a。它写道，

Thornhill MH、Dayer MJ、Prendergast B、Baddour LM、Jones S、Lockhart PB。用作心内膜炎预防的抗生素的不良反应的发生率和性质。J Antimicrob Chemother。2015；70：2382-2388。doi：10.1093/jac/dkv115

在第 e978 页，参考文献 68 阅读，

Jones TD、Baumgartner L、Bellows MT、Breese BB、Kuttner AG、McCarty M、Rammelkamp CH；代表美国心脏协会预防风湿热和细菌性心内膜炎委员会。通过控制链球菌感染预防风湿热和细菌性心内膜炎。流通。1955 年；11：317-320。

它已被替换为，

Khalil D、Hultin M、Rashid MU、Lund B. 单剂量阿莫西林后的口腔微生物群和抗性选择。临床微生物感染。2016;22:949.e1-949.e4。doi：10.1016/j.cmi.2016.08.008

在第 e978 页，参考文献 69 阅读，

Mortimer EA Jr, Rammelkamp CH Jr. 风湿热的预防。流通。1956；14：1144-1152。doi：10.1161/01.cir.14.6.1144

它已被替换为，

伍德曼 AJ、维迪克 J、纽曼 HN、马什 PD。阿莫西林反复高剂量预防对成年志愿者常驻口腔菌群的影响。J Med 微生物学杂志。1985:19:15-23。doi: 10.1099/00222615-19-1-15

这些更正已对文章的当前在线版本进行了修正，该版本可在 https://www.ahajournals.org/doi/10.1161/CIR.0000000000000969 获得